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The safety of predicting conversion from mild cognitive impairment (MCI) to Alzheimer’s disease 
(AD) dementia using APOE genotyping is unknown.  
METHODS 
We randomized 114 individuals with MCI to receive estimates of 3-year risk of conversion to AD 
dementia informed by APOE genotyping (disclosure arm) or not (nondisclosure arm) in a 
noninferiority clinical trial. Primary outcomes were anxiety and depression scores. Secondary 
outcomes included other psychological measures.  
RESULTS 
Upper confidence limits for randomization arm differences were 2.3 on the State Trait Anxiety Index 
and 0.5 on the Geriatric Depression Scale, below noninferiority margins of 3.3 and 1.0. Moreover, 
mean scores were lower in the disclosure arm than nondisclosure arm for test-related positive impact 
(difference: -1.9, indicating more positive feelings) and AD concern (difference: -0.3).  
DISCUSSION 
Providing genetic information to individuals with MCI about imminent risk for AD does not increase 
risks of anxiety or depression and may provide psychological benefits. 
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1. INTRODUCTION 
Genomic testing is increasingly used to diagnose and treat disease [1, 2], but its use to estimate risks 
for developing dementia remains controversial [3-6], particularly for conditions such as Alzheimer’s 
disease (AD) where proven strategies to prevent or delay disease onset are lacking. Consensus 
statements discourage genetic susceptibility testing for AD when individuals are asymptomatic for 
reasons that include its potential to cause psychological harm [7, 8]. People with symptoms that may 
suggest subclinical levels of disease may be especially vulnerable to anxiety, depression, or even 
suicidality [9]. 
Prior research has shown that disclosing APOE genotypes and communicating AD risk to 
asymptomatic individuals in clinical settings does not cause psychological harm for most individuals 
[10-12], although questions remain about direct-to-consumer contexts [13]. But these studies 
enrolled participants who, if they were to develop AD, were often decades away from developing 
symptoms. Questions remain about whether genetic risk disclosure is safe for individuals who have 
memory problems and may progress to AD dementia in the near future.  
To address this gap in knowledge, we conducted a randomized trial of individuals with amnestic mild 
cognitive impairment (MCI), a clinical syndrome characterized by memory problems without 
significant impairment in social or occupational functioning [14]. Approximately 10%-15% of MCI 
patients progress to AD dementia annually [15], depending on factors that include APOE genotype 
[16]. We compared participant outcomes when risk assessments for progressing to AD dementia 
within three years included or omitted disclosure of APOE genotypes. We hypothesized that 
participants who learned their APOE genotype would experience no greater anxiety or depression 
than participants who did not receive genotype disclosure. We hypothesized secondarily that 
participants who learned they were APOE ε4-positive would experience no greater anxiety or 
depression than participants who learned they were APOE ε4-negative. 
2. METHODS 
2.1 Design Overview  
As described in prior reports [10-12], the multidisciplinary Risk Evaluation and Education for 
Alzheimer’s Disease (REVEAL) Study group designed the protocol and risk disclosure procedures. 
Institutional review boards at each study site approved the protocol. APOE was genotyped at a 
Clinical Laboratory Improvement Amendments-certified facility (Athena Diagnostics). Methods for 
risk disclosure were reported previously [17]. 
After verbal consent and a phone interview to assess eligibility (Figure 1), participants met with a 
study clinician (typically a genetic counselor) for screening and to provide written consent. 
Participants also learned more about MCI and AD, and reviewed the benefits, risks, and limitations 
of genetic risk assessment for AD. Risks and limitations included potential difficulties coping with test 
results and the lack of “proven ways to prevent Alzheimer’s disease.” If participants met inclusion 
criteria and wished to proceed, blood was drawn for APOE genotyping. Participants were 
randomized 2:1 in blocks of 6 to groups that received APOE genotype disclosure (disclosure arm) or 
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did not receive genotype disclosure (nondisclosure arm). Randomization strata were defined by site 
and age. 
Approximately one month after the blood draw, participants returned to the clinic to receive results 
in person. Participants in both randomization arms received education about MCI and AD and 
personalized estimates from a study clinician about the likelihood they would progress to AD 
dementia within 3 years. These estimates, provided as part of a semi-scripted protocol, ranged from 
8% to 57% (see Appendix 2) and were created using data from the Memory Impairment Study [18]. 
Personalized estimates for progressing to AD dementia were based on participants’ age stratum and 
their MCI diagnoses [17]. For participants in the disclosure arm, personalized estimates of 
conversion to AD were additionally based on the presence or absence of a copy of the APOE ε4 allele 
(i.e., APOE ε4 heterozygotes and homozygotes were provided the same AD risk estimates). All 
personalized risk estimates included written information, a pictogram, and a line graph (see 
Appendix 3). Participants were followed for six months following disclosure sessions, with 
assessments conducted in person at 6 weeks and via telephone and mail at 6 months.  
A one year follow-up visit was originally planned, but was shortened to 6 months to reduce demands 
on participants and because prior studies [10] and anecdotal descriptions had suggested that there 
were no additional changes in psychosocial outcomes after 6 months. Participants in the genotype 
nondisclosure arm had the option to learn their APOE genotypes after completing their final follow-
up survey. 
2.2 Study Population 
We recruited individuals with amnestic mild cognitive impairment (MCI) who were aged 55-90 years 
from memory clinics, neurology and medicine departments, and AD centers. MCI was defined as 
having (1) a memory complaint, corroborated by an informant; (2) abnormal memory function, as 
documented by delayed recall on the Logical Memory II subtest of the Wechsler Memory Scale-
Revised; and (3) adequate general cognitive function (Mini-Mental State Examination (MMSE) score 
≥24 [19] or approval from a clinician for scores below 24). To ensure participants’ safety, we 
required participants to enroll and attend sessions with a companion. Exclusion criteria included 
severe anxiety or depression per a clinician’s judgment and informed by scores on mood scales. 
Additional details about the recruitment and safety monitoring protocols are provided in Appendix 
4. 
2.3 Outcome Measures 
Co-primary outcomes were time-averaged scores of anxiety, as assessed with a six-item version of 
the State-Trait Anxiety Inventory (STAI) [20]; and depression, assessed with the 15-item version of 
the Geriatric Depression Scale (GDS) [21, 22]. STAI scores were scaled to range from 20-80, and 
scores above 40 may warrant clinical concern [29, 30]. GDS scores ranged from 0-15, with higher 
scores indicating greater depression and scores of 5 or above indicate clinical concern [23, 24]. 
Secondary psychological measures included test-related distress, as measured by the Impact of 
Event Scale (IES) [25] (range: 0-75; higher scores indicate greater distress), and the individual 
subscales that comprised the Impact of Genetic Testing for Alzheimer’s Disease scale (IGT-AD) [26]: 
test-specific distress (range: 0-60; higher scores indicate greater distress) and positive test impact 
(range: 0-20; lower scores indicate greater positive feelings). We also assessed hopelessness with 
the four-item Beck Hopelessness Scale (BHS; range: 0-4, higher scores indicate greater hopelessness) 
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[27], and a 4-item AD concern scale (range: 1-5, higher scores indicate greater concern about AD) 
[28]. Participants who scored above 8 on the 15-item GDS, above 56 on the 6-item STAI, or endorsed 
at least 2 out of 4 statements on the BHS received additional follow-up and monitoring. Test-related 
distress and positive impact scales were administered only after AD risk assessments. All other 
measures were assessed at baseline and again at 6 weeks and 6 months after AD risk assessments. 
As in prior REVEAL Study trials [28-30], we also assessed participants’ risk perceptions at all time 
points by asking them to estimate their chances of AD conversion within the next three years on a 
scale of 0-100%. 
2.4 Statistical Analysis 
We planned to enroll 180 participants and provide 151 risk assessments. We used a noninferiority 
framework to test the primary hypothesis that participants in the genotype disclosure arm would 
report no greater anxiety or depression than participants in the nondisclosure arm [31]. We also 
used a noninferiority framework to test the secondary hypothesis that, within the genotype 
disclosure arm, participants who received APOE ε4-positive results would report no greater 
symptoms of anxiety or depression than participants who received APOE ε4-negative results. In this 
paper therefore, the phrase “noninferiority of genotype disclosure” means the comparison of scores 
of one group to another showed that genetic risk disclosure did not increase scores of psychological 
harm more than a margin of error from that of the nondisclosure group. 
We used t-tests and chi-squared tests to compare demographics of the randomization arms and to 
analyze who dropped out after randomization. We used chi-squared tests to compare dropout of 
study arms after randomization, but before results were communicated to participants. For all other 
analyses, we used generalized linear models fit with generalized estimating equations to compare 
time-averaged and time-specific outcomes by randomization arm or by APOE status. Analyses of 
STAI, GDS, IES, test-related distress with the IGT-AD, and BHS used a log link and gamma distribution 
because the distributions of these outcomes were highly skewed. A value of one was added to each 
of these scales, except the STAI, to shift their distributions away from zero. Analyses of positive 
impact, AD concern, and perceived risk for AD conversion used an identity link and normal 
distribution. Models included interaction terms between time and randomization status because 
prior work has shown that, when observed, the psychological impact of genetic information typically 
fades over time [32]. All models included terms for randomization status, time as a categorical 
variable, and interaction between time and randomization arm. We included age, gender, race, 
education, and, given imbalances by randomization status, marital status as covariates in analyses of 
continuous outcomes. The analytic approach followed our initial statistical analysis plans (these 
covariates were omitted from analyses of dichotomous outcomes because statistical models that 
included them were unstable). We also included the clinician who disclosed results as a covariate in 
the analyses of continuous outcomes to account for potential confounding [33]. We included 
baseline scores where available (STAI, GDS, BHS, and AD concern) given their strong associations 
with scores at follow-up and best practices [10, 34]. Analyses of STAI, GDS, BHS, and AD concern 
compared changes in scores from baseline. Analyses that compared participants by APOE status 
included a dichotomous variable to distinguish participants with no copies of the ε4 allele and 
participants with at least one copy, as well as terms for interaction between APOE status and 
randomization status, APOE status and time, and APOE status, randomization status, and time. 
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For noninferiority testing, we calculated 97.5% confidence limits (CL), using upper bounds of two-
sided CIs of (1 - 2α) × 100%, with α equal to 2.5% (0.05/2) to account for multiple testing across 2 
primary outcomes [35]. We asserted noninferiority (e.g., no greater anxiety or depression) if 97.5% 
confidence limits for the differences between randomization arms or APOE genotypes were below 
noninferiority margins (because all scales indicated worse scores with higher values, we were able to 
focus on upper bounds). The same approach was used to examine all outcomes at specific time 
points and all secondary psychological outcomes. More details about the margins that defined 
noninferiority and the statistical models are provided in Appendix 4.   
Analyses included all randomized participants. Analyses were conducted using R version 3.5.1 or 
SAS, version 9.4 (SAS Institute). We assumed that data were missing at random (up to 19 
participants were missing data on primary and secondary outcomes), and imputed missing data with 
fully conditional specification, running 100 iterations to create each of 20 imputed data sets.  
3. RESULTS 
We enrolled 146 of the 386 participants that we recruited (37.8%), and ultimately provided results to 
114 participants (Figure 1). Characteristics of participants who were provided risk assessments are 
summarized in Table 1. Participants were 74 years old, on average, and 75 (65.8%) had at least a 
bachelor’s degree. MMSE scores ranged from 21 to 30, with most participants (91.7%) scoring 24 or 
higher. A greater percentage of participants in the genotype disclosure arm were married compared 
to the nondisclosure arm (76.0% vs 51.3%, respectively, P value=.007). No other differences were 
observed by randomization status. Clinicians communicated results to between 4 and 47 participants 
each and did not differ in their likelihood of disclosing results to participants in either randomization 
arm (P value=.819).  
3.1 Randomization Arm Comparisons 
Mean anxiety and depression scores in both randomization arms were below cutoffs for concern at 
all time points (Table 2), and noninferiority of genotype disclosure was demonstrated in time-
averaged analyses (Figure 2). Mean adjusted time-averaged anxiety scores were 1.4 points lower in 
the disclosure arm than the nondisclosure arm, and the 97.5% confidence limit (2.3) was below the 
noninferiority margin (3.3). Mean adjusted time-averaged depression scores were the same in the 
disclosure and nondisclosure arms, and the 97.5% confidence limit (0.5) was below noninferiority 
margin (1.0). Noninferiority of genotype disclosure was also supported on time-averaged analyses of 
all secondary psychological outcomes. Similar patterns were observed at 6 weeks. Noninferiority of 
genotype disclosure at 6 months was observed only for positive impact and AD concern. Notably, 
participants were more likely to score above our pre-established cutoffs for increased monitoring on 
scales of anxiety, depression and hopelessness if they were randomized to genotype nondisclosure 
compared to genotype disclosure (28.9% vs 13.5%, respectively, P value=.050). 
3.2 Comparisons by APOE status 
Mean anxiety and depression scores were still below cutoffs for concern regardless of APOE ε4 
status (Table 3). Preplanned secondary analyses of participants in the disclosure arm that compared 
disclosure of APOE ε4-positive status against disclosure of APOE ε4-negative status were 
inconclusive (Figure 3), as upper bounds of the 97.5% confidence limits for both anxiety and 
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depression (4.1 and 1.0, respectively) were equal to or above margins for noninferiority (3.3 and 1.0, 
respectively). Furthermore, participants who received APOE ε4-positive results scored higher than 
those who received APOE ε4-negative results on time-averaged scales of test-related distress as 
measured by the IGT-AD (diff= 6.8, 95% confidence interval: 2.7 to 10.9), as well as all time point 
specific analyses of the same scale.  
3.2 Comparisons of Randomization Arms by APOE Status 
We conducted exploratory analyses that compared genotype disclosure to genotype nondisclosure 
for participants with specific APOE genotypes (Appendix 5). Among individuals who were APOE ε4-
negative, genotype disclosure was noninferior on time-averaged analyses of all psychological 
outcomes except anxiety and hopelessness. Moreover, scores were lower in the genotype disclosure 
arm on time-averaged scores of test-related distress as measured by the IGT-AD (diff=-7.4, 97.5% 
confidence limit (CL): -2.1), positive impact (diff= -3.1, 97.5% CL: -0.7), and AD concern (diff= -0.6, 
97.5% CL: -0.2). Similarly, analyses of 6-week outcomes among APOE ε4-negative participants 
showed noninferiority of genotype disclosure on all measures except hopelessness, and lower scores 
in the genotype disclosure arm on measures of test-related distress, as measured by the IGT-AD, and 
AD concern. At 6 months, noninferiority of genotype disclosure was observed only for test-related 
distress (both measures), positive impact, and AD concern. 
Among individuals who were APOE ε4-positive, genotype disclosure was noninferior to genotype 
nondisclosure on time-averaged measures of anxiety (diff= -2.3, 97.5% CL: 3.0 vs margin of 3.3), 
depression (diff= 0.3, 97.5% CL: .9 vs margin of 1.0), positive impact (diff= -0.6, 97.5% CL: 2.3 vs 
margin of 5.0), and hopelessness (diff= -0.1, 97.5% CL: 0.2 vs margin of 0.3). In time point-specific 
analyses of APOE ε4-positive participants, disclosure was demonstrated to be noninferior to 
nondisclosure at 6 weeks only for depression, positive impact, hopelessness, and AD concern, and 
for no psychological outcomes at 6 months except positive impact.  
 
3.3 Perceptions of Risk for Converting to AD 
Exploratory analyses also showed differences between randomization arms in perceived risk of 
progressing to AD within three years, contingent upon APOE status (Appendix 6). Among participants 
who were APOE ε4-negative, individuals in the genotype disclosure arm provided time-averaged 
estimates of their risk of progressing to AD that were an average of 11.3% lower in the disclosure 
arm than the nondisclosure arm (24.6% vs 36.0%, respectively, P value=.010), although differences 
were not significant at 6 weeks. No differences between randomization arms were observed at any 
time point or in time-averaged analyses among participants who were APOE ε4-positive (all P values 
≥ .165). Among participants in the disclosure arm, participants who were ε4-positive provided risk 
estimates for AD conversion that were 19.7% higher in time-averaged analyses than participants 
who were ε4-negative (44.3% vs 24.6%, respectively, P value<.001). Differences were also significant 
in time point-specific analyses. 
4. DISCUSSION 
This study showed that among individuals with MCI, disclosing genetic risk about progressing to AD 
dementia does not increase risks for clinically significant depression or anxiety, and overall reduced 
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concern about AD. It also resulted in more positive feelings about the risk assessment experience. 
These findings are consistent with results from prior trials that demonstrated the safety of disclosing 
genetic risk information about AD when provided to volunteer populations by clinicians in a well-
designed education and disclosure protocol [10-12, 36] and that showed psychological benefits for 
participants who learned that they were APOE ε4-negative. In this trial, it is likely that psychological 
benefits accrued, in part, because participants were expecting bad news given their mild memory 
problems. Similar responses have been observed in studies of genetic testing for conditions such as 
Huntington disease and Lynch syndrome, where identification of genetic risk factors have not caused 
clinically significant distress but negative results have provided emotional relief [37, 38]. Further 
supporting this rationale, we found participants estimated their likelihood of progressing to AD 
lower when their APOE ε4-negative status was disclosed rather than withheld, while no differences 
were observed when participants were APOE ε4-positive. 
Findings from our study have grown in importance as APOE genotyping has become more available. 
Trials of investigational medications, such as the A4 Trial [44] and the bapineuzumab trial [39] have 
used APOE genotyping to enrich or stratify their study populations. In the Generation Program [40], 
disclosure of APOE genotype is a mandatory part of determining trial eligibility. The design of these 
trials provide access to APOE genotyping results to their participants. In addition, some healthy 
individuals have obtained genetic risk information about AD through studies of precision medicine, 
physicians or direct-to-consumer options [13, 41, 42]. Most notably, 23andMe has FDA approval to 
include APOE results in their direct-to-consumer personal genome service [43]. Given the strong 
public interest in genetic susceptibility testing about AD [44, 45] it is likely that the number of 
individuals with mild memory problems – and healthy individuals – who pursue APOE-based risk 
information about AD will only continue to increase. 
In this trial, participants’ distress responses to risk disclosure appeared to be greater than in prior 
studies of asymptomatic, at-risk adults. Mean scores on both test-related distress scales were higher 
at all time points than previously observed [10-12, 36]. Differences in responses between trials may 
be the result of differences by trial in eligibility criteria (e.g., MCI in this trial, no MCI in prior trials), 
the magnitude of numeric risk estimates, or the proximity of AD conversion (i.e., risk was conveyed 
for the next three years in this trial, as opposed to by age 85 in prior trials) [46]. These findings 
highlight the heightened risk for distress in disclosing AD risk information to individuals with MCI, 
regardless of whether APOE genotypes are disclosed [47], and the need for carefully designed 
education, communication, and follow-up protocols when providing dementia information to 
individuals with MCI. 
Strengths of this study include an ethnically diverse study population, with 18% of participants self-
identifying as black or African American. Limitations include enrollment of a volunteer population of 
individuals who were generally more educated and may be better prepared to cope with higher-risk 
results than the population at-large [13]. Our study also mandated that participants enroll with a 
study partner who provided social support and responded to risk disclosure in ways that may have 
influenced study outcomes [17, 48], so the findings may not be generalizable to individuals lacking 
such social support. The wait for disclosure in the nondisclosure arm may have induced anticipatory 
anxiety. Lastly, we did not achieve our study enrollment targets, and provided risk assessments to 
fewer participants than planned (151 planned vs 114 actual). Moreover, loss to follow-up and 
missing data at each time point also increased the width of confidence intervals. Nonetheless, 
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sample sizes were sufficient to confirm noninferiority of genetic risk disclosure in analyses that 
compared randomization arms on primary outcome measures. Tests of hypotheses that compared 
APOE ε4-positive and ε4-negative participants within the disclosure arm were inconclusive, however, 
possibly because these analyses were underpowered. 
Importantly, our data suggest that including genetic information to estimate the likelihood that 
individuals with MCI will progress to AD dementia may reassure people who are ε4-negative. 
Although short-term test-related distress was clearly higher among participants who learned they 
were ε4-positive rather than ε4-negative, no differences were noted on general measures of anxiety 
or depression. Given the ever-increasing accessibility of genetic information, our findings provide 
encouraging data about the safety and personal utility of genetic risk disclosure via standardized 
education and counseling protocols among populations who are often considered to be most 
vulnerable to potential harms. These results provide reassurance that APOE genotypes, as well as 
common genotypes for other neurodegenerative diseases (such as LRRK2 for Parkinson disease), 
may be disclosed safely even in persons who have already begun to show clinical symptoms of the 
condition itself. Since enrollment for new experimental treatments may be increasingly genotype-
specific in the future, our work suggests that even participants with MCI can receive information 
about their APOE status without increasing risks for depression or anxiety. 
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Figure 1. Study flow diagram. 
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Table 1. Baseline characteristics of the 114 participants who attended risk disclosure sessions. 






Age in years    
     57-70 30 (40%) 14 (36%)  
     71-77 19 (25%) 10 (26%)  
     78-89 26 (35%) 15 (38%)  
Gender    
     Female 39 (52%) 18 (46%)  
     Male 36 (48%) 21 (54%)  
Self-identified race    
     Black 11 (15%)  9 (23%)  
     White 64 (85%) 30 (77%)  
Years of education, mean (SD) 16.2 (2.7) 16.4 (2.9)  
Median household income $70-$99K $50-69K  
Currently married 57 (76%) 20 (51%) * 
Has AD-affected family member 43 (59%) 17 (44%)  
ε4-positive 39 (52%) 17 (44%)  
MMSE score, mean (SD) 27.4 (1.9) 27.0 (2.4)  
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Mood scale scores, mean (SD)    
     Anxiety (range: 20-80) 36.5 (10.9) 36.3 (12.0)  
     Depression (range: 0-15)  2.1 (2.0)  2.6 (2.6)  
     Hopelessness (range: 0-4)  0.3 (0.6)  0.5 (0.8)  
     AD concern (range: 1-5) 3.7 (0.9) 3.6 (0.7)  
Perceived risk of AD conversion (range: 0-100%), 
mean (SD) 
34.9% (28.5%) 30.2% (24.2%)  
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Table 2. Mean psychological outcome scores and standard errors, by randomization arm and time 
after risk disclosure sessions* 
 
 Disclosure Arm (n=75)  Nondisclosure Arm (n=39) 
 
Time-
Averaged 6 Week  6 Months  
Time-
Averaged 6 Weeks 6 Months 
Anxiety 
35.6 (1.0) 35.6 
(1.0) 
35.6 (1.5)  37.0 (1.6) 38.2 
(1.9) 
35.8 (2.0) 
Depression 1.9 (0.2) 1.8 (0.1) 1.9 (0.2)  1.9 (0.2) 2.0 (0.2) 1.7 (0.3) 
Test-related distress 
(IES) 
11.8 (1.3) 11.4 
(1.5) 





10.0 (1.0) 10.0 
(1.1) 




9.3 (0.5) 9.2 (0.6) 9.4 (0.6)  11.1 (0.7) 10.4 
(0.8) 
11.9 (0.9) 
Hopelessness 0.3 (0.1) 0.3 (0.1) 0.4 (0.1)  0.4 (0.1) 0.4 (0.1) 0.4 (0.1) 
AD concern 3.3 (0.1) 3.2 (0.1) 3.4 (0.1)  3.6 (0.1) 3.6 (0.1) 3.6 (0.2) 
* Scores were estimated using generalized estimating equations, with adjustment for demographic 
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Disclosure Arm APOE ε4-Positive (n=39)  APOE ε4-Negative (n=36) 
Anxiety 35.6 (1.4) 36.0 (1.6) 35.1 (1.9)  35.7 (1.6) 35.3 (1.4) 36.1 (2.4) 
Depression 2.1 (0.2) 2.1 (0.2) 2.1 (0.3)  1.7 (0.2) 1.5 (0.2) 1.8 (0.3) 
Test-related 
distress (IES) 
12.9 (1.8) 12.6 (1.9) 13.2 (2.0)  10.4 (1.9) 10.1 (2.3) 10.8 (2.1) 
Test-related 
distress (IGT-AD) 
13.5 (1.7) 13.1 (1.9) 13.8 (2.0)  6.7 (1.2) 7.0 (1.4) 6.4 (1.3) 
Positive impact 10.0 (0.7) 10.0 (0.9) 10.0 (0.8)  8.5 (0.8) 8.3 (1.0) 8.7 (1.0) 
Hopelessness 0.3 (0.1) 0.2 (0.1) 0.4 (0.1)  0.4 (0.1) 0.3 (0.1) 0.4 (0.1) 
AD concern 3.4 (0.1) 3.3 (0.2) 3.6 (0.2)  3.1 (0.1) 3.0 (0.1) 3.1 (0.1) 
        
Nondisclosure Arm APOE ε4-Positive (n=17)  APOE ε4-Negative (n=22) 
Anxiety 37.9 (2.3) 37.9 (2.3) 37.9 (2.8)  36.1 (2.1) 38.3 (2.9) 34.1 (2.6) 
Depression 1.8 (0.2) 1.9 (0.3) 1.7 (0.4)  1.9 (0.3) 2.1 (0.4) 1.7 (0.4) 
Test-related 
distress (IES) 
9.2 (1.9) 11.3 (2.4) 7.5 (1.9)  13.0 (2.1) 12.2 (2.4) 13.8 (2.8) 
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Test-related 
distress (IGT-AD) 
9.7 (2.0) 11.0 (2.2) 8.6 (2.3)  14.1 (2.4) 15.8 (2.8) 12.5 (2.7) 
Positive impact 10.6 (1.3) 10.2 (1.4) 11.0 (1.6)  11.6 (1.0) 10.6 (1.1) 12.6 (1.3) 
Hopelessness 0.5 (0.1) 0.5 (0.2) 0.4 (0.2)  0.4 (0.2) 0.4 (0.2) 0.5 (0.2) 
AD concern 3.4 (0.1) 3.5 (0.2) 3.4 (0.2)  3.7 (0.2) 3.7 (0.2) 3.8 (0.2) 
* Scores were estimated using generalized estimating equations, with adjustment for demographic 
factors, disclosing clinician, and baseline values. Models for all outcomes used a log link and gamma 
distribution. 
 
 
 
